Abstract 2112P
Background
The WHO (World Health Organization) defines elderly as individuals aged 60 years or older in developing countries. It is known that due to sociodemographic changes such as increased life expectancy, there was an increase in the prevalence of cancer diagnosis in this population subgroup. Associated with the fact that historically these individuals are underrepresented in the main oncological clinical studies, the challenge of a better way of evaluating these patients, who inherently have different physiological characteristics, arises. In this context, the Comprehensive Geriatric Assessment (GGA) is consolidated as an adequate application tool. This study aims to evaluate, based on the domains of the CGA, elderly patients with malignant neoplasm of the digestive tract who will start chemotherapy treatment and associate it with the tolerability of the treatment after 3 months.
Methods
This prospective study included patients with neoplasia of the digestive tract: esophagus, stomach, pancreas, biliary tract, colon and rectum, evaluated at baseline and after 3 months of chemotherapy. Patients aged 60 years or older were selected. The CGA was applied at the beginning of the treatment. Treatment tolerability was defined in this study by toxicity and maintenance or not of the chosen treatment at the end of 3 months. The data were registered in Excel and subsequently imported into IBM-SPSS Statistics version 28 for comparative analysis between groups. This study was approved by the ethics committee (CAAE:30127320.0.0000.5505). All patients signed a Term of Free and Informed Consent before inclusion.
Results
50 patients (median age: 68), colorectal (42%). Stage II: 7 patients, III:18, IV: 25.Correlated with toxicity: IADL (Instrumental Activities of Daily Living) and nutritional status. Dependent for IADL developed more G3 toxicity (p= 0.048) and were unable to continue treatment: the Lawton scale (p=0.020) ;Pfeffer questionnaire (p=0.024).Malnourished developed more G3 toxicity (p=0.003) and suspended/modified treatment (p=0.002).
Conclusions
The evaluation of functionality and nutrition domains were associated with toxicity and maintenance of treatment after 3 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06